Pfizer Inc ((PFE)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Pfizer Inc. is currently conducting a Phase 1 clinical study titled A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND ANTI TUMOR ACTIVITY OF PF-07799933 (ARRY-440) AS A SINGLE AGENT AND IN COMBINATION THERAPY IN PARTICIPANTS 16 YEARS AND OLDER WITH ADVANCED SOLID TUMORS WITH BRAF ALTERATIONS. The study aims to assess the safety and effectiveness of PF-07799933, both as a standalone treatment and in combination with other drugs, for patients with advanced solid tumors with BRAF alterations.
The study is testing PF-07799933, a tablet taken orally, alone and in combination with binimetinib (another oral tablet) and cetuximab (an intravenous injection). These treatments target advanced solid tumors that have not responded to existing therapies.
This interventional study is non-randomized and follows a sequential intervention model without masking. Its primary purpose is treatment, focusing on evaluating the drug’s impact on tumor activity.
The study began on July 5, 2022, and is currently recruiting participants. The primary completion and estimated completion dates are not specified, but the last update was submitted on July 8, 2025. These dates are crucial for tracking the study’s progress and potential market release timelines.
This clinical update could influence Pfizer’s stock performance positively, as successful results may enhance investor confidence and market positioning against competitors in oncology treatments. The study’s progress is an indicator of Pfizer’s commitment to advancing cancer therapies.
The study is ongoing, and further details can be accessed on the ClinicalTrials portal.